TATTON: Phase 1b trial of AZD9291 for EGFR-mutant lung cancer
Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
Immunotherapy for lung cancer and trial of ramucirumab plus pembrolizumab
Combining TKIs with checkpoint inhibitors for prostate cancer – is this the way forward?
CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer